DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

Advocates and patients with rare diseases spent Tuesday morning talking with lawmakers and educating the public as part of ...

When a test determined that Walter had hemophilia, his Omaha owner joined a group seeking to raise $50,000 for a clinical ...

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

New research, from several surveys, shows U.S. consumers are planning to pinch more pennies.

The first hemophilia B patient at the Loma Linda University Health Hemophilia Treatment Center to receive Hympavzi is a ...

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Market Drivers: Key drivers include increasing prevalence of immunodeficiency disorders globally, rising demand for plasma-derived medicinal products, and a growing geriatric population. The market ...

The Franklin County Board of Commissioners has passed a resolution urging the Benton Franklin Health District (BFHD) to cease ...

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.